PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• PTC Therapeutics, Inc. has an average analyst rating of "Moderate Buy", with 9 buy recommendations and 1 sell recommendation from 15 brokerages.
• The company recently reported earnings of ($0.83) per share, surpassing analyst estimates of ($1.07), and its revenue for the quarter was $178.88 million.
• Insider trading activity includes CEO Matthew B. Klein selling over 10,000 shares, reducing his ownership by 3.08%, with corporate insiders owning 5.50% of the stock.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $69.00.

Several equities analysts have commented on PTCT shares. UBS Group increased their target price on PTC Therapeutics from $71.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Truist Financial upped their price objective on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Robert W. Baird set a $70.00 price objective on shares of PTC Therapeutics in a report on Friday, August 8th. Barclays boosted their target price on shares of PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 29th. Finally, Wells Fargo & Company dropped their price target on shares of PTC Therapeutics from $79.00 to $73.00 and set an "overweight" rating for the company in a research note on Wednesday, August 20th.

PTC Therapeutics Stock Performance

Shares of PTCT traded down $0.09 during mid-day trading on Friday, reaching $58.33. The company had a trading volume of 917,296 shares, compared to its average volume of 1,304,915. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of 8.37 and a beta of 0.53. The company's 50 day simple moving average is $49.78 and its 200 day simple moving average is $49.34. PTC Therapeutics has a 1-year low of $30.98 and a 1-year high of $59.00.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.24. The business had revenue of $178.88 million during the quarter, compared to the consensus estimate of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The firm's revenue was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.29) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that PTC Therapeutics will post -4.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Pierre Gravier sold 2,516 shares of the firm's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total transaction of $124,441.36. Following the completion of the transaction, the chief financial officer directly owned 71,920 shares of the company's stock, valued at $3,557,163.20. This trade represents a 3.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Pauwels sold 39,850 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $56.92, for a total value of $2,268,262.00. Following the completion of the sale, the insider directly owned 72,912 shares of the company's stock, valued at approximately $4,150,151.04. The trade was a 35.34% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,439 shares of company stock valued at $3,115,539. Company insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Quantbot Technologies LP raised its stake in PTC Therapeutics by 545.5% during the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 551 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 320 shares in the last quarter. GAMMA Investing LLC lifted its stake in PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 441 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of PTC Therapeutics by 247.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 814 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of PTC Therapeutics during the first quarter valued at about $61,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.